Missouri Cancer Associates

Columbia, Missouri 65201

12 studies enrolling now · 73 studies all time

What they study most

Adenocarcinoma of the Colon, Advanced Breast Cancer, Anal Cancer, Androgen-independent Prostate Cancer, Bladder Cancer, Breast Adenocarcinoma, Breast Cancer, CRC (Colorectal Cancer), Carcinoma, Non-Small-Cell Lung, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Clear Cell Renal Cell Carcinoma, Colon Adenocarcinoma

Studies at this site

• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) — Recruiting now
• A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) — Recruiting now
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma — Recruiting now
• Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) — Recruiting now
• A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer — Recruiting now
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Recruiting now
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) — Recruiting now
• A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) — Recruiting now
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer — Recruiting now
• A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) — Recruiting now
• BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) — Recruiting now
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) — Running, not enrolling
• Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia — Running, not enrolling
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery — Completed
• Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer — Completed
• Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer — Running, not enrolling
• Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma — Completed
• PhII ICb With/Without Erbitux in MBC Pts — Running, not enrolling
• Palbociclib in Real World Practice — Completed
• Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial — Status unconfirmed
• A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer — Completed
• TAC Versus TC for Adjuvant Breast Cancer — Completed
• Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer — Completed
• A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer — Completed
• Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant — Completed
• The BEACON Study (Breast Cancer Outcomes With NKTR-102) — Completed
• A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer — Stopped early
• A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma — Completed
• Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive — Completed
• AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy — Completed
• Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy — Completed
• Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer — Completed
• Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer — Completed
• Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer — Completed
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed
• Phase II Sunitinib Prog Met AIPC — Completed
• Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer — Completed
• Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer — Completed
• Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer — Completed
• Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients — Completed
• Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer — Completed
• Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) — Completed
• Ixabepilone + Carboplatin Metastatic Breast Cancer — Completed
• Docetaxel+Oxali+/-Cetux Met Gastric/GEJ — Completed
• Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer — Completed
• Adj TC + Herceptin Early Stage Breast Cancer — Completed
• Gemzar, Cisp, Sunitinib Urothelial Ca — Completed
• Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer — Completed
• Combination Chemotherapy in Treating Patients With Bladder Cancer — Completed